Tradjenta

Type: Product
Name: Tradjenta
First reported Aug 11 2014 - Updated Aug 11 2014 - 1 reports

J&J's diabetes combo wins FDA nod in a fast-crowding space

Johnson & Johnson's ($JNJ) canagliflozin was the first to win FDA approval among a new class of diabetes therapies, and now it's the star of the first such combination therapy to pass agency muster, helping the drug stand out in an increasingly cluttered ... [Published FierceBiotech - Aug 11 2014]
First reported Aug 07 2014 - Updated Aug 07 2014 - 2 reports

Eli Lilly and Boehringer Ingelheim move towards diabetes market lead

Eli Lilly and its partner, Boehringer Ingelheim (BI), have taken another step towards owning the most comprehensive diabetes portfolio in the industry w ith the recent approval of Jardiance in the  US.According to an analyst with research and consulting ... [Published Pharma Field - Aug 07 2014]
First reported Aug 06 2014 - Updated Aug 06 2014 - 1 reports

Lilly and BI Close In On Diabetes Market Lead

With the recent approval of Jardiance in the US, Eli Lilly and partner Boehringer Ingelheim (BI) “have taken another step towards owning the most comprehensive diabetes portfolio in the industry”, according to research and consulting firm GlobalData ... [Published Pharmaceutical Executive - Aug 06 2014]
First reported Aug 04 2014 - Updated Aug 04 2014 - 1 reports

Boehringer Ingelheim receives two FDA approvals

Boehringer Ingelheim today announced the U.S. approved two different products at the end of last week.Striverdi® (olodaterol) Respimat® was approved in the US as a long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients ... [Published European Pharmaceutical Review - Aug 04 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

Eli Lilly's (LLY) CEO John Lechleiter on Q2 2014 Results - Earnings Call Transcript

OperatorLadies and gentlemen, thank you for standing by. Welcome to the Q 2014 earnings call. At this time, all participants are in a listen only mode. Later we will conduct a question-and-answer session. (Operator Instructions). As a reminder, this conference ... [Published Seeking Alpha - Jul 25 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

TRADJENTA (Linagliptin) Tablet, Film Coated [Cardinal Health]

First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

TRADJENTA (Linagliptin) Tablet, Film Coated [Cardinal Health]

First reported Jun 17 2014 - Updated Jun 17 2014 - 1 reports

Two phase III trials of empagliflozin/linagliptin combo tablet showed reduction in blood glucose levels in adults withT2D

Two phase III clinical trials found the investigational combination tablet of empagliflozin and linagliptin reduced blood glucose levels in adults with type 2 diabetes (T2D), Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company ... [Published PharmaBiz - Jun 17 2014]
First reported Apr 24 2014 - Updated Apr 24 2014 - 1 reports

Possible Link Between Heart Failure And Onglyza Diabetes Type 2 Drug Is Being Investigated By FDA, As Announced In February 2014

This Cardiovascular Side Effect Issue Also Involves Kombygilyze XR, A Saxagliptin - Metformin Combo Diabetes Medication (Posted by Tom Lamb at DrugInjuryWatch.com ) AstraZeneca's diabetes drugs Onglyza and Kombygilyze, both of which contain ... [Published Drug Injury Watch - Apr 24 2014]
First reported Apr 20 2014 - Updated Apr 21 2014 - 1 reports

TRADJENTA (Linagliptin) Tablet, Film Coated [Boehringer Ingelheim Pharmaceuticals, Inc.]

First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

US FDA accepts NDA filing of empagliflozin and linagliptin combo drug to treat adults with type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company announced that the US Food and Drug Administration (FDA) accepted the filing of the New Drug Application (NDA) for the investigational combination tablet of empagliflozin and linagliptin ... [Published PharmaBiz - Apr 16 2014]
First reported Mar 07 2014 - Updated Mar 07 2014 - 1 reports

What Do Pharma's "High Performers" Have in Common?

A new study of high-performing pharma companies reveals science-based innovation strategies and patient-outcome-based commercial models are now the key drivers of growth. Anne O’Riordan reports.A select group of high performing pharma companies are significantly ... [Published Pharmaceutical Executive - Mar 07 2014]

Quotes

...0 per cent with the combination," said Christophe Arbet-Engels, vice president, metabolic clinical development and medical affairs, BIPI. "People with type 2 diabetes must often take more than one medication to adequately control their blood sugar levels. If approved, this combination tablet with two mechanisms of action that lower A1C through different pathways in a single pill could be an important treatment option for physicians and patients."
From the February 2014 "FDA Drug Safety Communication: FDA to review heart failure risk with diabetes drug saxagliptin (marketed as Onglyza and Kombiglyze XR)" Safety Announcement:
...said Christophe Arbet-Engels, vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "Adults living with type 2 diabetes often take more than one therapy to manage their condition, and we hope the combination of these two products will help them improve control of their blood sugar."
...the plaintiffs and defendants update the judge on the progress of the litigation and any problems that have developed," said Resource4thePeople. "We will monitor these developments and continue to update consumers who are following this litigation or are considering seeking compensation in connection with these allegations." The latest figures*** provided by the U S Judicial Panel for Multidistrict Litigation shows that there are now 163 cases in the multidistrict litigation...

More Content

All (18) | News (14) | Reports (0) | Blogs (4) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
J&J's diabetes combo wins FDA nod in a fast-cro... [Published FierceBiotech - Aug 11 2014]
Eli Lilly and Boehringer Ingelheim move towards... [Published Pharma Field - Aug 07 2014]
Lilly and Boehringer closing in on diabetes mar... [Published Pharma Letter - Aug 07 2014]
Lilly and BI Close In On Diabetes Market Lead [Published Pharmaceutical Executive - Aug 06 2014]
Boehringer Ingelheim receives two FDA approvals [Published European Pharmaceutical Review - Aug 04 2014]
Eli Lilly's (LLY) CEO John Lechleiter on Q2 201... [Published Seeking Alpha - Jul 25 2014]
TRADJENTA (Linagliptin) Tablet, Film Coated [Ca... [Published DailyMed Drug Label Updates for the last seven ... - Jul 24 2014]
TRADJENTA (Linagliptin) Tablet, Film Coated [Ca... [Published DailyMed Drug Label Updates for the last seven ... - Jul 22 2014]
Two phase III trials of empagliflozin/linaglipt... [Published PharmaBiz - Jun 17 2014]
Possible Link Between Heart Failure And Onglyza... [Published Drug Injury Watch - Apr 24 2014]
TRADJENTA (Linagliptin) Tablet, Film Coated [Bo... [Published DailyMed Drug Label Updates for the last seven ... - Apr 20 2014]
US FDA accepts NDA filing of empagliflozin and ... [Published PharmaBiz - Apr 16 2014]
What Do Pharma's "High Performers" Have in Common? [Published Pharmaceutical Executive - Mar 07 2014]
The New Metrics of Market Success [Published Pharmaceutical Executive - Mar 03 2014]
Januvia Pancreatic Cancer Allegations Help: Res... [Published PRWeb - Feb 27 2014]
Januvia Pancreatic Cancer Allegations Alert: Re... [Published PRWeb - Jan 19 2014]
Byetta Pancreatic Cancer Allegations Attorneys:... [Published PRWeb - Dec 19 2013]
Byetta Pancreatic Cancer Allegation Attorneys: ... [Published PRWeb - Nov 27 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
TRADJENTA (Linagliptin) Tablet, Film Coated [Ca... [Published DailyMed Drug Label Updates for the last seven ... - Jul 24 2014]
Updated Date: Jul 22, 2014 EST ...
TRADJENTA (Linagliptin) Tablet, Film Coated [Ca... [Published DailyMed Drug Label Updates for the last seven ... - Jul 22 2014]
Updated Date: Jul 22, 2014 EST ...
Possible Link Between Heart Failure And Onglyza... [Published Drug Injury Watch - Apr 24 2014]
This Cardiovascular Side Effect Issue Also Involves Kombygilyze XR, A Saxagliptin - Metformin Combo Diabetes Medication (Posted by Tom Lamb at DrugInjuryWatch.com ) AstraZeneca's diabetes drugs Onglyza and Kombygilyze, both of which contain ...
TRADJENTA (Linagliptin) Tablet, Film Coated [Bo... [Published DailyMed Drug Label Updates for the last seven ... - Apr 20 2014]
Updated Date: Apr 15, 2014 EST ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.